In this review, we will analyze LEAP-2’s effects from a metabolic point of view with a focus on metabolic hormones (e.g., ghrelin, GH, and insulin), and discuss LEAP-2’s potential as a promising therapeutic target for obesity. This evidence concerns the gene GHRL and obesity due to melanocortin 4 receptor deficiency.